



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
John M. Covert  
Robert C. Millionig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim  
Jeffrey T. Helvey  
Eldora L. Ellison  
Donald R. Banowitz

Peter A. Jackman  
Brian J. Del Buono  
Mark Fox Evens  
Vincent L. Capuano  
Elizabeth J. Haanes  
Michael D. Specht  
Kevin W. McCabe  
Glenn J. Perry  
Theodore A. Wood  
Edward W. Yee  
Grant E. Reed  
Jason D. Eisenberg  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth

Lori A. Gordon  
Laura A. Vogel  
Shannon A. Carroll  
Anbar F. Khal  
Michelle K. Holoubek  
Marsha A. Rose  
Scott A. Schaller  
Lei Zhou  
W. Blake Coblentz  
James J. Pohl  
John T. Haran  
Mark W. Rygiel  
Michael R. Malek\*  
Carla Ji-Eun Kim  
Doyle A. Siever\*  
Ulrike Winkler Jenks  
Paul A. Calvo  
C. Matthew Rozier\*  
Randall K. Baldwin

Daniel J. Nevriy  
Lori M. Brandes  
Jeffrey K. Mills\*  
Mita Mukherjee\*  
Scott M. Woodhouse\*  
Christian A. Camarce\*  
Richard D. Collier III\*  
Keisha Hyton-Rodic  
Bonnie Nannenga-Combs  
Alyssa K. Sandrowitz\*  
Jonathan M. Strang\*  
Ishan P. Weerakoon\*  
  
Registered Patent Agents\*  
Karen R. Markowicz  
Matthew J. Dowd  
Peter A. Socarras  
Danielle L. Letting  
Steven C. Oppenheimer

Aaron S. Lukas  
Gaurav Asthana  
Stephanie L. Elmer  
Robert E. Bakin  
Salvador M. Bezos  
Yasser Mourtada

Of Counsel  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie  
Christopher P. Wrist  
David C. Isaacson

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

August 20, 2008

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:  
(202) 772-8856  
INTERNET ADDRESS:  
KMCCABE@SKGF.COM

**Art Unit 1644**

**Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Appl. No. 10/765,097; Filed: January 28, 2004  
For: **Means for Detection and Purification of CD8+T Lymphocyte  
Populations Specific to Peptides Presented in the Context of HLA**  
Inventors: **LANG et al.**  
Our Ref: 2512.0240002/KWM (2102-183-DIV)

Sir:

Transmitted herewith for appropriate action are the following documents:

1. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Credit Card Payment Form (PTO-2038) in the amount of \$460.00 to cover the two-month extension of time fee;
3. Petition for Extension of Time Under 37 C.F.R. § 1.136(a);
4. Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
5. 1 page of a paper copy of the substitute Sequence Listing;
6. A computer readable copy of the substitute Sequence Listing; and
7. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
August 20, 2008  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kevin W. McCabe  
Attorney for Applicants  
Registration No. 41,182

KWM/ROM  
Enclosures

863306\_1.DOC



# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/765,097	01/28/2004	Francois Lang	BECK1170-1	9827
7590 Beckman Coulter, Inc. c/o DLA PIPER US LLP Suite 1100 4365 Executive Drive San Diego, CA 92121-2133		05/20/2008	EXAMINER DIBRINO, MARIANNE NMN	
			ART UNIT 1644	PAPER NUMBER
			MAIL DATE 05/20/2008	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10765097	1/28/04	LANG ET AL.	BECK1170-1

Beckman Coulter, Inc.  
c/o DLA PIPER US LLP  
Suite 1100  
4365 Executive Drive  
San Diego, CA 92121-2133

**EXAMINER**

DiBrino Marianne

ART UNIT	PAPER
----------	-------

1644

20080516

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**


**Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Marianne DiBrino, Ph.D.

/G.R. Ewoldt/  
Primary Examiner, Art Unit 1644



## Notice to Comply

Application No.  
10/765,097

Applicant(s)  
Lang et al.

Examiner  
Marianne DiBrino

Art Unit  
1644

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Applicant must provide data at <150> and <151> for prior applications and filing dates respectively.

#### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951  
For CRF Submission Help, call (571) 272-2510  
PatentIn Software Program Support  
Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845  
PatentIn Software is Available At [www.USPTO.gov](http://www.USPTO.gov)

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

